{"filings":[{"id":99588,"accession_number":"0001171843-26-002799","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.","Gross margin 64.2% vs 56.1% YoY on operational execution and favorable mix.","GAAP loss from continuing ops $5.1M ($0.37 diluted); adjusted net income $3.8M ($0.27 diluted).","Adjusted EBITDA $4.3M vs $0.1M prior year; FY2026 guidance reaffirmed (revenue $114-122.5M).","Board members Jellison and Larsen resign effective 2026 annual meeting; share repurchase $15M completed at avg $10.76/share."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":29612000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115681,"accession_number":"0001193125-26-073401","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.","FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.","Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.","FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.","EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":112819000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115680,"accession_number":"0001193125-26-007655","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.","Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.","Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).","Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.","Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132111,"accession_number":"0001171843-25-007003","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.","Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.","Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.","Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.","Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":82204000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148681,"accession_number":"0001171843-25-004810","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%","Regenerative Solutions revenue rose 41% driven by Integrity implant outperformance (full-year 2024 surpassed in H1 2025)","Hyalofast Phase III trial missed co-primary endpoints but showed statistically significant improvements in secondary endpoints; final PMA module on track for H2 2025","Company reaffirms 2025 revenue/EBITDA guidance but revises long-term outlook for Hyalofast launch potential delay to 2027","Operating expenses down 17% YoY; production yield issues resolved in June 2025 with no patient impact"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":54387000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148680,"accession_number":"0001171843-25-004809","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.","Statistically significant improvements on secondary endpoints: KOOS Sports & Recreation, Quality of Life, and Total KOOS.","Safety profile comparable to microfracture; company plans to file final PMA module in H2 2025.","Over 35,000 patients treated outside U.S. since 2009; independent studies support safety and efficacy.","Study impacted by higher dropout in microfracture arm and COVID-related missed visits, reducing evaluable sample size."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167558,"accession_number":"0001171843-25-004062","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anika Therapeutics stockholders approve 475,000-share increase in incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.","All three Class II director nominees elected: Blanchard, Capper, Larsen.","Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.","Deloitte & Touche ratified as independent auditor for fiscal 2025.","Annual meeting had 86.13% of voting power present; no opposition to board's solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167557,"accession_number":"0001171843-25-003005","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.","Adjusted net loss from continuing ops $0.9M ($0.06/share); Adjusted EBITDA $0.1M; cash $53.4M, no debt.","Updated FY2025 guidance: OEM revenue $62-65M (down 16-20%); Adj. EBITDA -3% to 3% (prev 8-10%).","Integrity procedures on pace to more than double in 2025; over 300 surgeries in Q1; Regenerative Solutions portfolio up 33% YoY.","Key regulatory milestones: Hyalofast second PMA module filed, MDR approved; Cingal NDA path cleared with FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":26168000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167556,"accession_number":"0001171843-25-002148","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Anika Therapeutics announces departure of COO Anne Nunes, eliminates position","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne Nunes departs as Chief Operations Officer effective April 25, 2025.","She receives severance per her Executive Retention Agreement (filed as Exhibit 10.14 to 10-K).","Stephen Griffin (EVP, CFO, COO) assumes manufacturing and operations functions.","Company eliminates Chief Operations Officer role; no replacement planned.","Griffin's annual compensation remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184847,"accession_number":"0001171843-25-001437","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).","Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).","Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.","FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).","Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184846,"accession_number":"0001171843-25-001388","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).","Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.","Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.","Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.","Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201439,"accession_number":"0001171843-24-005923","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).","Integrity Implant System grew 40%+ sequentially, >500 surgeries since launch, Regenerative Solutions up 17%.","Exiting Arthrosurface (sold) and Parcus Medical (divestiture planned) to focus on HA technology and Commercial Channel.","Updated 2024 guidance: Commercial Channel +14% to +19%, OEM -8% to -10%, Adj EBITDA $16-18M; restructuring charges $3-5M cash, $27-29M non-cash.","First Hyalofast PMA module filed Oct 28; Cingal NDA path progress including acquisition of Aristospan NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":121197000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201438,"accession_number":"0001171843-24-005922","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.","Announced intention to sell Parcus Medical sports medicine business as part of strategic review.","Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.","Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217443,"accession_number":"0001171843-24-004607","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).","Net loss $0.1M ($0.01/sh); adjusted net income $2.5M ($0.17/sh); adjusted EBITDA $6.3M.","Full market release of Integrity Implant System (HA scaffold) in July; >300 cases by >60 surgeons.","Guidance: FY2024 revenue $168-$173M (1-4% growth); adjusted EBITDA towards lower end of $25-$30M.","New $40M share repurchase program; $15M under 10b5-1 plan initiated May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":82444000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217442,"accession_number":"0001171843-24-003900","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anika Therapeutics stockholders elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Sheryl L. Conley, William R. Jellison, Stephen O. Richard as Class I directors (2027 term).","Ratified Deloitte & Touche LLP as independent auditor: 12,337,376 for, 43,654 against.","Say-on-pay proposal passed on a non-binding advisory basis: 11,020,273 for, 129,717 against.","Annual meeting turnout: 12,387,064 shares voted, representing 83.37% of entitled voting power.","No contested solicitations; all board proposals carried with substantial majority support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237307,"accession_number":"0001171843-24-003136","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.","Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.","Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.","Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.","New directors join Capital Allocation Committee; no prior relationships or transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237306,"accession_number":"0001171843-24-002673","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.","Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.","Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.","Levitz's separation includes continued salary through year-end and a general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237305,"accession_number":"0001171843-24-002672","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).","Adjusted EBITDA improved to $2.5M from ($1.2M) in Q1 2023; FY2024 adj EBITDA guidance $25-30M (midpoint up >75%).","Cost reduction initiatives completed, achieving $10M annualized savings; severance costs $0.8M in Q1.","Business highlights: extended Canadian distribution deal through 2030; >10,000 X-Twist anchors sold; Integrity Implant >200 cases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":40523000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}